Sherry X. Yang, MD, PhD, on Breast Cancer: New Recurrence Score Data From the TAILORx Trial
AACR Annual Meeting 2023
Sherry X. Yang, MD, PhD, of the National Cancer Institute, discusses findings from the TAILORx trial, which showed that, despite chemotherapy, patients with high recurrence scores continue to have a poor prognosis. This result suggests the need to develop new management strategies for patients with early-stage breast cancer. (Abstract LB119)
Transcript
Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Cancer recurrence has been frequently utilized as a surrogate endpoint in clinical studies, particularly in the contact genomic ISIS in several cancer types. Oncotype DX recurrence score was originally developed against distant recurrence for prognosis in estrogen receptor positive, no negative breast cancer.
Primary objectives our study were to assess whether recurrence score has more prognostic weight for recurrence than survival, and to evaluate associations between recurrence score and overall survival, invasive disease-free survival, and recurrence-free interval with based on recurrence as reference in [inaudible 00:01:11] trial population.
Recurrence score was associated with this recurrence-free interval, independent of other prognostic factors. However, recurrence score mid-range 11 to 25 and high-range scores 26 and greater did not provide independent information for survival prognosis in this adjuvant trial population and median follow up about eight years. High-range, but not mid-range scores was associated with invasive disease-free survival. Among 499 death events in this intention to treat population, one third were due to breast cancer, all had the DFS related events. Those including 35% breast cancer, 25% other cancers, 24% other disease and 16% unknown.
It is important to note overall survival and recurrence-free interval had similar event numbers. This recurrence has less events. Overall recurrence score demonstrate the more prognostic weight for recurrence than survival. The data called for developing clinical and molecular ISIS to evaluate mortality risk and disease risk with potential to further increase overall survival, which may have impact on choice, adjuvant chemotherapy, optimal duration, endocrine therapy, and other relevant treatment.
Related Videos
The ASCO Post Staff
Carmen E. Guerra, MD, MSCE, of the University of Pennsylvania Abramson Cancer Center, discusses the ways in which community outreach, programs to help patients access cancer clinical trials, and institutional policies such as ASCO’s Just Ask program can help increase equity, diversity, and inclusion in cancer clinical trials and reduce unconscious bias.
The ASCO Post Staff
Pierce K.H. Chow, PhD, MBBS, of the National Cancer Centre, Singapore and Duke-NUS Medical School, discusses phase III findings showing that, for patients with hepatocellular carcinoma at high risk of disease recurrence, adjuvant therapy with atezolizumab plus bevacizumab after resection or thermal ablation was more effective than active surveillance. According to Dr. Chow, these results could lead to reassessment of surgical resection in this disease. (Abstract CT003)
The ASCO Post Staff
John V. Heymach, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses phase III results from the AEGEAN trial, which showed that patients with treatment-naive, resectable, non–small cell lung cancer (NSCLC) who received neoadjuvant durvalumab plus chemotherapy and adjuvant durvalumab monotherapy had improved event-free survival and pathologic complete response, compared with those who received neoadjuvant chemotherapy alone. (Abstract CT005)
The ASCO Post Staff
Timothy A. Yap, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses safety and efficacy data on three different PARP inhibitors combined with the ATR inhibitor camonsertib in patients with solid tumors harboring DNA damage response alterations. The findings showed that low-dose intermittent regimens of camonsertib and different PARP inhibitor combinations were safe. In addition, anticancer activity was observed in patients with platinum- and PARP inhibitor–resistant tumors. Patients with late-line ovarian cancer derived the most benefit from therapy. (Abstract CT018)
The ASCO Post Staff
Karriem S. Watson, DHSc, MPH, of the National Institutes of Health All of Us Research Program, discusses the importance of engaging in clinical trials for those who are underrepresented in biomedical research. Community engagement is a proven and effective tool, Dr. Watson says, to enhance participation in research by increasing access to and awareness of medical studies and has already been shown to expand the reach of therapies, improving cancer outcomes. (Abstract PL03-05)
